Global Parkinson’s Disease Treatment Market – Industry Analysis and Forecast (2017-2024) _ by Drug Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors and Others), by Patient Care Setting (Hospitals and Clinics), by Distribution Channel (Hospital Pharmacies, Retailer Pharmacies and Online Pharmacies), and by Geography

Market Scenario

Global Parkinson’s Disease Treatment Market is expected to reach USD 6.48 Billion by 2024 from USD 4.02 Billion in 2016 at CAGR of 6.15% (Detailed analysis of the market CAGR is provided in the report). Global Parkinson's Disease Trearment Market Parkinson’s Disease is the combination of progressive, degenerative neurological motor disorder, primarily affecting the dopaminergic cells of the brain. Rigidity, tremor, bradykinesia and postural instability are some of the common symptoms of Parkinson’s Disease. Global Parkinson’s Disease Treatment Market is segmented by drug class, patient care setting, distribution channel, and geography. Drug Class segment is sub-segmented as levodopa/carbidopa, dopamine receptor agonists, Mao-inhibitors and others. Distribution channel segment is classified as hospital pharmacies, retailer pharmacies, and online pharmacies. Hospital pharmacies segment is expected to dominate the market during the forecast period. A rising number of patient visits to the hospital due to the availability of diagnostic laboratories is expected to fuel the segment growth. Patient care setting segment is bifurcated as hospitals and clinics. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Increasing prevalence and rise in incidences of Parkinson’s disease across the developed countries are trending the overall Global Parkinson’s Disease Treatment Market. However, the availability of conventional treatment methods will restrain the market growth. APAC is expected to register the highest growth rate in Parkinson’s Disease Treatment Market during the forecast period followed by North America and Europe. The increasing number of generic drug manufacturers and rising aging population in this region will fuel the Parkinson’s Disease Treatment Market in the APAC region. Key Highlights: • Assessment of market definition along with the identification of key players and an analysis of their strategies to determine the competitive outlook of the market, opportunities, drivers, restraints, and challenges for this market during the forecast period • Complete quantitative analysis of the industry from 2016 to 2024 to enable the stakeholders to capitalize on the prevailing market opportunities • In-depth analysis of the industry on the basis of market segments, market dynamics, market size, competition & companies involved value chain • Global Parkinson’s Disease Treatment Market analysis and comprehensive segmentation with respect to the drug class, patient care setting, distribution channel, and geography to assist in strategic business planning • Global Parkinson’s Disease Treatment Market analysis and forecast for five major geographies North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions Research Methodology: The research methodology used in this report contains various secondary sources including Bloomberg, Hoovers, and Factiva. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Parkinson’s Disease Treatment Market globally. Key Players in the Global Parkinson’s Disease Treatment Market Are: • GSK • Novartis • UCB • F. Hoffmann-La Roche AG • STADA Arzneimittel AG • Acadia • Wockhardt • Sun Pharma • Lundbeck • Valeant Pharmaceuticals • Abbvie • Impax • Boehringer Ingelheim • Teva • Merck Key Target Audience: • Research and Consulting Firms as well as Venture capitalists, private equity firms, and startup companies • Academic institutions • Parkinson’s disease treatment dealers and suppliers • Parkinson’s disease treatment product manufacturers • Parkinson’s disease associations • Human identification service providers • Contract research organizations (CROs) • Government Bodies Scope of the Report: Research report categorizes the Global Parkinson’s Disease Treatment Market based on drug class, patient care setting, distribution channel, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Parkinson’s Disease Treatment Market with key developments in companies and market trends. Global Parkinson’s Disease Treatment Market, By Drug Class: • Levodopa/carbidopa • Dopamine Receptor Agonists • MAO-Inhibitors • COMT-inhibitors • Anticholinergics • Other Drugs Global Parkinson’s Disease Treatment Market, By Distribution Channel: • Hospital Pharmacies • Retailer Pharmacies • Online Pharmacies Global Parkinson’s Disease Treatment Market, By Patient Care Setting: • Hospitals • Clinics Global Parkinson’s Disease Treatment Market, By Geography: • North America • Europe • Asia Pacific • Middle East & Africa • Latin America Available Customization: Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client. Global Bioinformatics Services Market - Global Industry Analysis and Forecast 2024

Table of Contents

1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. END-USER OVERVIEW 4.1. Value Chain Analysis 4.2. Key Trends 5. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS (2017-2024) 5.1. Introduction 5.2. Levodopa/carbidopa 5.2.1. Levodopa/carbidopa Market Overview 5.2.2. Levodopa/carbidopa Market Size & Forecast 5.3. Dopamine Receptor Agonists 5.3.1. Dopamine Receptor Agonists Market Overview 5.3.2. Dopamine Receptor Agonists Market Size & Forecast 5.4. MAO-Inhibitors 5.4.1. MAO-Inhibitors Market Overview 5.4.2. MAO-Inhibitors Market Size & Forecast 5.5. COMT-inhibitors 5.5.1. COMT-inhibitors Market Overview 5.5.2. COMT-inhibitors Market Size & Forecast 5.6. Anticholinergics 5.6.1. Anticholinergics Market Overview 5.6.2. Anticholinergics Market Size & Forecast 5.7. Other Drugs 5.7.1. Other Drugs Market Overview 5.7.2. Other Drugs Market Size & Forecast 6. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2017-2024) 6.1. Introduction 6.2. Hospital Pharmacies 6.2.1. Hospital Pharmacies Market Overview 6.2.2. Hospital Pharmacies Market Size & Forecast 6.3. Retailer Pharmacies 6.3.1. Retailer Pharmacies Market Overview 6.3.2. Retailer Pharmacies Market Size & Forecast 6.4. Online Pharmacies 6.4.1. Online Pharmacies Market Overview 6.4.2. Online Pharmacies Market Size & Forecast 7. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING (2017-2024) 7.1. Introduction 7.2. Hospitals 7.2.1. Hospitals Market Overview 7.2.2. Hospitals Market Size & Forecast 7.3. Clinics 7.3.1. Clinics Market Overview 7.3.2. Clinics Market Size & Forecast 8. GLOBAL PARKINSON’S DISEASE TREATMENT MARKET, BY GEOGRAPHY (2017-2024) 8.1. North America Parkinson’s Disease Treatment Market 8.1.1. North America Parkinson’s Disease Treatment Market, By Drug Class 8.1.2. North America Parkinson’s Disease Treatment Market, By Distribution Channel 8.1.3. North America Parkinson’s Disease Treatment Market, By Patient Care Setting 8.1.4. North America Parkinson’s Disease Treatment Market, by Region 8.1.4.1. U.S. Parkinson’s Disease Treatment Market 8.1.4.2. Canada Parkinson’s Disease Treatment Market 8.1.4.3. Mexico Parkinson’s Disease Treatment Market 8.2. Europe Parkinson’s Disease Treatment Market 8.2.1. Europe Parkinson’s Disease Treatment Market, By Drug Class 8.2.2. Europe Parkinson’s Disease Treatment Market, By Distribution Channel 8.2.3. Europe Parkinson’s Disease Treatment Market, By Patient Care Setting 8.2.4. Europe Global Parkinson’s Disease Treatment Market, by Region 8.2.4.1. France Parkinson’s Disease Treatment Market 8.2.4.2. Germany Parkinson’s Disease Treatment Market 8.2.4.3. U.K. Parkinson’s Disease Treatment Market 8.2.4.4. Italy Parkinson’s Disease Treatment Market 8.2.4.5. Spain Parkinson’s Disease Treatment Market 8.2.4.6. Rest of Europe Parkinson’s Disease Treatment Market 8.3. Asia Pacific Parkinson’s Disease Treatment Market 8.3.1. Asia-Pacific Parkinson’s Disease Treatment Market, By Drug Class 8.3.2. Asia-Pacific Parkinson’s Disease Treatment Market, By Distribution Channel 8.3.3. Asia-Pacific Parkinson’s Disease Treatment Market, By Patient Care Setting 8.3.4. Asia-Pacific Parkinson’s Disease Treatment Market, by Region 8.3.4.1. China Parkinson’s Disease Treatment Market 8.3.4.2. Japan Parkinson’s Disease Treatment Market 8.3.4.3. India Parkinson’s Disease Treatment Market 8.3.4.4. South Korea Parkinson’s Disease Treatment Market 8.3.4.5. Rest of Asia Pacific Parkinson’s Disease Treatment Market 8.4. Middle East & Africa Parkinson’s Disease Treatment Market 8.4.1. Middle East & Africa Parkinson’s Disease Treatment Market, By Drug Class 8.4.2. Middle East & Africa Parkinson’s Disease Treatment Market, By Distribution Channel 8.4.3. Middle East & Africa Parkinson’s Disease Treatment Market, By Patient Care Setting 8.4.4. Middle East & Africa Parkinson’s Disease Treatment Market, by Region 8.4.4.1. South Africa Parkinson’s Disease Treatment Market 8.4.4.2. Rest of Middle East and Africa Parkinson’s Disease Treatment Market 8.5. Latin America Parkinson’s Disease Treatment Market 8.5.1. Latin America Parkinson’s Disease Treatment Market, By Drug Class 8.5.2. Latin America Parkinson’s Disease Treatment Market, By Distribution Channel 8.5.3. Latin America Parkinson’s Disease Treatment Market, By Patient Care Setting 8.5.4. Latin America Parkinson’s Disease Treatment Market, by Region 8.5.4.1. Brazil Parkinson’s Disease Treatment Market 8.5.4.2. Rest of Latin America Parkinson’s Disease Treatment Market 9. MARKET COMPETITION ANALYSIS 9.1 Market Share/Positioning Analysis 9.2 Key Innovators 9.3 Company Profiles 9.3.1 GSK 9.3.1.1 Overview 9.3.1.2 Products/ End-User 9.3.1.3 Strategy 9.3.1.4 Key Developments 9.3.2 Novartis 9.3.2.1 Overview 9.3.2.2 Products/ End-User 9.3.2.3 Strategy 9.3.2.4 Key Developments 9.3.3 UCB 9.3.3.1 Overview 9.3.3.2 Products/ End-User 9.3.3.3 Strategy 9.3.3.4 Key Developments 9.3.4 F. Hoffmann-La Roche AG 9.3.4.1 Overview 9.3.4.2 Products/ End-User 9.3.4.3 Strategy 9.3.4.4 Key Developments 9.3.5 STADA Arzneimittel AG 9.3.5.1 Overview 9.3.5.2 Products/ End-User 9.3.5.3 Strategy 9.3.5.4 Key Developments 9.3.6 Acadia 9.3.6.1 Overview 9.3.6.2 Products/ End-User 9.3.6.3 Strategy 9.3.6.4 Key Developments 9.3.7 Wockhardt 9.3.7.1 Overview 9.3.7.2 Products/ End-User 9.3.7.3 Strategy 9.3.7.4 Key Development 9.3.8 Sun Pharma 9.3.8.1 Overview 9.3.8.2 Products/ End-User 9.3.8.3 Strategy 9.3.8.4 Key Development 9.3.9 Lundbeck 9.3.9.1 Overview 9.3.9.2 Products/ End-User 9.3.9.3 Strategy 9.3.9.4 Key Development 9.3.10 Valeant Pharmaceuticals 9.3.10.1 Overview 9.3.10.2 Products/ End-User 9.3.10.3 Strategy 9.3.10.4 Key Development 9.3.11 Abbvie 9.3.11.1 Overview 9.3.11.2 Products/ End-User 9.3.11.3 Strategy 9.3.11.4 Key Development 9.3.12 Impax 9.3.12.1 Overview 9.3.12.2 Products/ End-User 9.3.12.3 Strategy 9.3.12.4 Key Development 9.3.13 Boehringer Ingelheim 9.3.13.1 Overview 9.3.13.2 Products/ End-User 9.3.13.3 Strategy 9.3.13.4 Key Development 9.3.14 Teva 9.3.14.1 Overview 9.3.14.2 Products/ End-User 9.3.14.3 Strategy 9.3.14.4 Key Development 9.3.15 Merck 9.3.15.1 Overview 9.3.15.2 Products/ End-User 9.3.15.3 Strategy 9.3.15.4 Key Development

Inquiry Before Buying

Request Sample

About This Report

Report ID6655
Category Healthcare
Publisher Name
No of Pages
Total Views
Published Date
Contact Us
Call Now